Kardigan has secured a $300 million Series A funding round, marking it as the second-largest of 2025. This trend of substantial VC investments, particularly over $100 million, is anticipated to persist due to the increasing number of start-ups with clinical-stage assets and investor concerns regarding adequate funding for programs. Additionally, Eli Lilly and Andreessen Horowitz have introduced a new VC fund with a potential of up to $500 million. This financial landscape highlights the growing confidence in biotech investments and the demand for significant capital in the industry.